<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37774729</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-5247</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Microbe</Title><ISOAbbreviation>Lancet Microbe</ISOAbbreviation></Journal><ArticleTitle>Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.</ArticleTitle><Pagination><StartPage>e923</StartPage><EndPage>e930</EndPage><MedlinePgn>e923-e930</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2666-5247(23)00215-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-5247(23)00215-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">The polio eradication endgame required the withdrawal of Sabin type 2 from the oral poliovirus vaccine and introduction of one or more dose of inactivated poliovirus vaccine (IPV) into routine immunisation schedules. However, the duration of single-dose IPV immunity is unknown. We aimed to address this deficiency.</AbstractText><AbstractText Label="METHODS">In this phase 4, open-label, non-randomised clinical trial, we assessed single-dose IPV immunity. Two groups of infants or children were screened: the first group had previously received IPV at 14 weeks of age or older (previous IPV group; age &gt;2 years); the second had not previously received IPV (no previous IPV group; age 7-12 months). At enrolment, all participants received an IPV dose. Children in the no previous IPV group received a second IPV dose at day 30. Blood was collected three times in each group: on days 0, 7, and 30 in the previous IPV group and on days 0, 30, and 37 in the no previous IPV group. Poliovirus antibody was measured by microneutralisation assay. Immunity was defined as the presence of a detectable antibody or a rapid anamnestic response (ie, priming). We used the χ<sup>2</sup> to compare proportions and the Mann-Whitney U test to assess continuous variables. To assess safety, vaccinees were observed for 30 min, caregivers for each participating child reported adverse events after each follow-up visit and were questioned during each follow-up visit regarding any adverse events during the intervening period. Adverse events were recorded and graded according to the severity of clinical symptoms. The study is registered with ClinicalTrials.gov, NCT03723837.</AbstractText><AbstractText Label="FINDINGS">From Nov 18, 2018, to July 31, 2019, 502 participants enrolled in the study, 458 (255 [65%] boys and 203 [44%] girls) were included in the per protocol analysis: 234 (93%) in the previous IPV group and 224 (90%) in the no previous IPV group. In the previous IPV group, 28 months after one IPV dose 233 (&gt;99%) of 234 children had persistence of poliovirus type 2 immunity (100 [43%] of 234 children were seropositive; 133 [99%] of 134 were seronegative and primed). In the no previous IPV group, 30 days after one IPV dose all 224 (100%) children who were type 2 poliovirus naive had seroconverted (223 [&gt;99%] children) or were primed (one [&lt;1%]). No adverse events were deemed attributable to study interventions.</AbstractText><AbstractText Label="INTERPRETATION">A single IPV dose administered at 14 weeks of age or older is highly immunogenic and induces nearly universal type 2 immunity (seroconversion and priming), with immunity persisting for at least 28 months. The polio eradication initiative should prioritise first IPV dose administration to mitigate the paralytic burden caused by poliovirus type 2.</AbstractText><AbstractText Label="FUNDING">WHO and Rotary International.</AbstractText><CopyrightInformation>© 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Arun K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Harish</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estivariz</LastName><ForeName>Concepcion F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajracharaya</LastName><ForeName>Luna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rai</LastName><ForeName>Ganesh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatric Medicine, Kanti Children's Hospital, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ganesh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Patan Hospital, Patan Academy of Health Sciences, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherchand</LastName><ForeName>Jeevan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Kathryn A V</ForeName><Initials>KAV</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavan</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyaseelan</LastName><ForeName>Vishali</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>WHO, Geneva, Switzerland. Electronic address: rolandsutter@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Laxman P</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03723837</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Microbe</MedlineTA><NlmUniqueID>101769019</NlmUniqueID><ISSNLinking>2666-5247</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Microbe. 2023 Dec;4(12):e963. doi: 10.1016/S2666-5247(23)00371-3</RefSource><PMID Version="1">38042153</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37774729</ArticleId><ArticleId IdType="mid">NIHMS1979863</ArticleId><ArticleId IdType="pmc">PMC10976347</ArticleId><ArticleId IdType="doi">10.1016/S2666-5247(23)00215-X</ArticleId><ArticleId IdType="pii">S2666-5247(23)00215-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Assembly. Global eradication of poliomyelitis by the year 2000. Resolutions of 41st World Health Assembly. Geneva: World Health Organization, 1988.</Citation></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication—worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 650–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Deblina Datta S, Tangermann RH, Reef S, William Schluter W, Adams A. National, regional and global certification bodies for polio eradication: a framework for verifying measles elimination. J Infect Dis 2017; 216 (suppl 1): S351–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853984</ArticleId><ArticleId IdType="pubmed">28838172</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Report from the Twentieth meeting of the Global Commission for the Certification of Eradication of Poliomyelitis. 2019. https://polioeradication.org/wp-content/uploads/2016/07/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf (accessed
May 17, 2022).</Citation></Reference><Reference><Citation>Lee SE, Greene SA, Burns CC, Tallis G, Wassilak SGF, Bolu O. Progress Toward Poliomyelitis Eradication—Worldwide, January 2021–March 2023. MMWR Morb Mortal Wkly Rep 2023; 72: 517–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10208367</ArticleId><ArticleId IdType="pubmed">37167156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296: 356–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010; 362: 2360–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">20573924</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio eradication &amp; endgame strategic plan 2013–2018. Geneva: World Health Organization, 2013.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio endgame &amp; legacy—implementation, best practices, and lessons learned. J Infect Dis 2017; 216 (suppl 1): S1–379.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 2020; 368: 401–05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1691–99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater—New York, June–August 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 1065–68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidor E. Poliovirus Vaccinated—Inactivated. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edn). Philadelphia, PA: Elsevier, 2013: 841–65.</Citation></Reference><Reference><Citation>Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 1: 897–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">2895828</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis 2014; 210 (suppl 1): S439–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368: 416–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad M, Verma H, Deshpande J, et al. Immunogenicity of fractional dose inactivated poliovirus vaccine in India. J Pediatric Infect Dis Soc 2022; 11: 60–68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865014</ArticleId><ArticleId IdType="pubmed">34791350</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Kovacs SD, Vanderende K, et al. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. Vaccine 2021; 39: 5814–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9059229</ArticleId><ArticleId IdType="pubmed">34481702</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 2015; 33: 6816–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007; 356: 1536–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65: 934–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaumik SK, Kulkarni RR, Weldon WC, et al. Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in Macaque models: support for at least 2 doses. Clin Infect Dis 2018; 67 (suppl 1): S66–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206122</ArticleId><ArticleId IdType="pubmed">30376091</ArticleId></ArticleIdList></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016; 1387: 145–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem AF, Mach O, Yousafzai MT, et al. One-year decline of poliovirus antibodies following fractional-dose inactivated poliovirus vaccine. J Infect Dis 2021; 223: 1214–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8030725</ArticleId><ArticleId IdType="pubmed">32798224</ArticleId></ArticleIdList></Reference><Reference><Citation>Böttiger M Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990; 8: 443–45.</Citation><ArticleIdList><ArticleId IdType="pubmed">2251870</ArticleId></ArticleIdList></Reference><Reference><Citation>Böttiger M A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 1987; 19: 595–601.</Citation><ArticleIdList><ArticleId IdType="pubmed">2831621</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999; 162: 5011–18.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202050</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai S, Diener T, Tan BK, et al. An unusual case of vaccineassociated paralytic poliomyelitis. Can J Infect Dis Med Microbiol 2014; 25: 227–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173946</ArticleId><ArticleId IdType="pubmed">25285130</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020—conclusions and recommendations. Wkly Epidemiol Rec 2020; 48: 585–608.</Citation></Reference><Reference><Citation>World Health Organization. SAGE April 2022 meeting highlights. 2022. https://www.who.int/news/item/11-04-2022-sage-april-2022-meeting-highlights (accessed
May 31, 2022).</Citation></Reference><Reference><Citation>Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007; 195: 12–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17152004</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz AB, Verma H, Jeyaseelan V, et al. One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomised clinical trial in Bangladesh. J Infect Dis 2022; 226: 1319–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9574668</ArticleId><ArticleId IdType="pubmed">35575051</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartz TA, Handsher R, Stoeckel P, et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989; 5: 143–45.</Citation><ArticleIdList><ArticleId IdType="pubmed">2767220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, Clemens R, Leroux-Roels G, et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis 2016; 16: 321–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108810</ArticleId><ArticleId IdType="pubmed">26719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Molodecky NA, Pallansch MA, Sutter RW. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine 2017; 35: 2993–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423713</ArticleId><ArticleId IdType="pubmed">28434691</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Mach O, et al. Does simultaneous administration of bivalent (Types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis 2018; 67 (suppl 1): S51–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206124</ArticleId><ArticleId IdType="pubmed">30376088</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014; 345: 922–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin JF, Bandyopadhyay AS, Sutter R. Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication. J Infect Dis 2021; 224 (suppl 2): S398–404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482017</ArticleId><ArticleId IdType="pubmed">34590135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>